Oncogenic Therapeutics announced that the Ministry of Food and Drug Safety (MFDS) has approved a Phase 3 clinical trial to expand the indication of its domestic P‑CAB drug Zaqibo (active ingredient jastafrazan) to Helicobacter pylori eradication therapy. The trial will enroll 414 H. pylori‑positive patients and will be conducted at 24 institutions throughout South Korea. This move follows the drug’s recent growth in prescriptions for gastro‑esophageal reflux disease and gastric ulcer, and aims to secure an additional growth driver in the H. pylori treatment market.
Regulatory UpdatesSep 14, 2026•3 min read
Oncogenic Therapeutics launches Phase 3 trial of Zaqibo (Jastafrazan) for H. pylori eradication
Oncogenic Therapeutics secured MFDS approval for a Phase 3 study of its P‑CAB drug Zaqibo to treat Helicobacter pylori infection in 414 patients across 24 Korean sites.
Compiled by the Pharmacountry team · Source: KPA News
Topics:
Ratings
(0)
(0)
(0)
(0)
(0)
Leave your rating